Skip to content
value.today

Reata Pharmaceuticals Inc.

Formerly Reata Discovery, Inc.

Total raised
$369 M
4 rounds on record
Latest round
$50 M
Jun 2020
First round on record
Sep 2009
Today
Acquired
Acquired by Biogen Inc.

Acquired

Matched to this startup by its exact name; the buyer's report is the source.

Acquisition of Reata Pharmaceuticals Inc.
AcquiredBuyerAcquisition dateCompletionPriceStakeSource
Reata Pharmaceuticals, IncBiogen Inc.2023—$7.2 B—Annual report

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Reata Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2020$50 MNo. 4$50 to $250 million

Reata Pharmaceuticals Inc.: Raise no. 4, Jun 2020

Investors in this round

2 investors had bought by the notice of Jun 25, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Colin J. Meyer, M.D. · Executive Officer
  • Dawn C. Bir · Executive Officer
  • J. Warren Huff · Executive Officer, Director
  • Manmeet S. Soni · Executive Officer
  • Michael D. Wortley · Executive Officer
  • J. Kent McGaughy, Jr. · Director
  • Jack B. Nielsen · Director
  • James E. Bass · Director
  • William D. McCLellan, Jr. · Director
  • William E. Rose · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael D. Wortley, Chief Legal Officer and Executive Vice President. Source: SEC Form D, newest notice filed Jun 25, 2020. Read the notice at the SEC.

equitySEC
Nov 2010$300 MNo. 3$250 million to $1 billion

Reata Pharmaceuticals Inc.: Raise no. 3, Nov 2010

Investors in this round

1 investor had bought by the notice of Jul 13, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$300 M of $300 M offered
Smallest investment taken
$300,000,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Casi M. DeYoung · Executive Officer
  • Catherine M. Fanning · Executive Officer
  • Colin W. Meyer · Executive Officer
  • J. Warren Huff · Executive Officer, Director
  • Jason D. Wilson · Executive Officer
  • John M. Walling · Executive Officer
  • Melean M. Visnick · Executive Officer
  • Melissa W. Krauth · Executive Officer
  • Paul Christian Audhya · Executive Officer
  • Robert M. Kral, Jr. · Executive Officer
  • William Christian Wigley · Executive Officer
  • Dennis B. Stone · Director
  • Edward W. Rose · Director
  • Jack B. Nielsen · Director
  • James B. Bass · Director
  • Kent Christian McGaughy · Director
  • Nancy M. Wysenski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “A portion of the gross proceeds was used to pay dividends to stockholders, including executive officers and directors who are stockholders. The number above does not reflect the payment of such dividends to stockholders.”

Signed by J. Warren Huff, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Jul 13, 2011. Read the notice at the SEC.

equitySEC
Feb 2010$2 MNo. 2Under $2 million

Reata Pharmaceuticals Inc.: Raise no. 2, Feb 2010

Investors in this round

1 investor had bought by the notice of Feb 26, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Colin A. Meyer · Executive Officer
  • Eric Christian Grossman · Executive Officer
  • J. Warren Huff · Executive Officer, Director
  • Jason D. Wilson · Executive Officer
  • John M. Walling · Executive Officer
  • Melean M. Visnick · Executive Officer
  • Melissa A. Krauth · Executive Officer
  • Robert M. Kral, Jr. · Executive Officer
  • William Christian Wigley · Executive Officer
  • Charles A. Sanders · Director
  • Dennis B. Stone · Director
  • Edward W. Rose · Director
  • Jack B. Nielsen · Director
  • James B. Bass · Director
  • Kent Christian McGaughy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Warren Huff, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Feb 26, 2010. Read the notice at the SEC.

equitySEC
Sep 2009$17 MNo. 1$10 to $50 million

Reata Pharmaceuticals Inc.: Raise no. 1, Sep 2009

Investors in this round

30 investors had bought by the notice of Oct 5, 2010: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $79 M offered; $62 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$3,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Colin A. Meyer · Executive Officer
  • Eric Christian Grossman · Executive Officer
  • J. Warren Huff · Executive Officer, Director
  • Jason D. Wilson · Executive Officer
  • John M. Walling · Executive Officer
  • Melean M. Visnick · Executive Officer
  • Melissa A. Krauth · Executive Officer
  • Robert M. Kral, Jr. · Executive Officer
  • William Christian Wigley · Executive Officer
  • Charles A. Sanders · Director
  • Dennis B. Stone · Director
  • Edward W. Rose · Director
  • Jack B. Nielsen · Director
  • James B. Bass · Director
  • Kent Christian McGaughy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Represents payment of salaries and bonuses to executive officers.”

Signed by J. Warren Huff, Chief Executive Officer and President. Source: SEC Form D and 1 amendment, newest notice filed Oct 5, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Reata Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2020

That is all the official record says: Reata Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Reata Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Reata Pharmaceuticals Inc.
NameRoleNamed in
Colin J. Meyer, M.D.Executive officerJun 2020
Dawn C. BirExecutive officerJun 2020
J. Warren HuffExecutive officerJun 2020
Manmeet S. SoniExecutive officerJun 2020
Michael D. WortleyExecutive officerJun 2020
Casi M. DeYoungExecutive officerJul 2011
Catherine M. FanningExecutive officerJul 2011
Colin W. MeyerExecutive officerJul 2011
Jason D. WilsonExecutive officerJul 2011
John M. WallingExecutive officerJul 2011
Melean M. VisnickExecutive officerJul 2011
Melissa W. KrauthExecutive officerJul 2011
Paul Christian AudhyaExecutive officerJul 2011
Robert M. Kral, Jr.Executive officerJul 2011
William Christian WigleyExecutive officerJul 2011
Colin A. MeyerExecutive officerOct 2010
Eric Christian GrossmanExecutive officerOct 2010
Melissa A. KrauthExecutive officerOct 2010
J. Kent McGaughy, Jr.DirectorJun 2020
J. Warren HuffDirectorJun 2020
Jack B. NielsenDirectorJun 2020
James E. BassDirectorJun 2020
William D. McCLellan, Jr.DirectorJun 2020
William E. RoseDirectorJun 2020
Dennis B. StoneDirectorJul 2011
Edward W. RoseDirectorJul 2011
James B. BassDirectorJul 2011
Kent Christian McGaughyDirectorJul 2011
Nancy M. WysenskiDirectorJul 2011
Charles A. SandersDirectorOct 2010

Acquired (Jan 1, 2023). Acquired by Biogen Inc..